ICHNOS SCIENCES ANNOUNCES PRESENTATION OF ADDITIONAL PRECLINICAL DATA ON ISB 1442 FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA AT AACR 2022 ANNUAL MEETING
/PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing novel multispecific antibodies for the treatment of cancer using the...
New York United States Cyril Konto Stefano Sammicheli Head Of Communications Prnewswire Ichnos Sciences Inc
Source: prnewswire.com